IL17A and COVID-19: Finally, the only randomized controlled trial to exist for IL-17 inhibition as treatment for COVID-19 looked at the use of ixekizumab, low-dose IL-2, or colchicine (an indirect IL-6 inhibitor) compared to standard of care in 60 participants [104].